Nasdaq Lbph News Today

Longboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued on Friday, Benzinga reports. They currently have a $60.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 178.68% from the company’s current price. Other […]

HC Wainwright reaffirmed their buy rating on shares of Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $60.00 price objective on the stock. LBPH has been the topic of a number of other reports. Guggenheim increased their price objective on […]

Citigroup began coverage on shares of Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) in a research report sent to investors on Friday, Marketbeat reports. The firm issued a buy rating and a $40.00 price target on the stock. Several other equities analysts have also recently weighed in on the company. Cantor Fitzgerald raised their price objective […]

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 2,440,000 shares, a growth of 43.5% from the January 15th total of 1,700,000 shares. Based on an average daily volume of 1,200,000 shares, […]

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $23.15, but opened at $23.87. Longboard Pharmaceuticals shares last traded at $22.52, with a volume of 40,554 shares trading hands. Analyst Ratings Changes LBPH has been the subject of a number […]

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Free Report) – HC Wainwright decreased their FY2023 earnings estimates for shares of Longboard Pharmaceuticals in a report issued on Monday, January 8th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($2.28) for the year, down from their previous estimate of ($2.14). […]

Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) had its price target boosted by HC Wainwright from $25.00 to $60.00 in a report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Longboard Pharmaceuticals’ Q4 2023 earnings at ($0.52) EPS, FY2023 earnings at ($2.28) EPS, […]

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $24.85, but opened at $23.79. Longboard Pharmaceuticals shares last traded at $24.55, with a volume of 64,839 shares trading hands. Wall Street Analysts Forecast Growth LBPH has been the subject […]

Cantor Fitzgerald reissued their overweight rating on shares of Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. The firm currently has a $35.00 price objective on the stock, up from their previous price objective of $16.00. Cantor Fitzgerald also issued estimates for Longboard Pharmaceuticals’ FY2023 […]

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Get Free Report) was the recipient of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 569,600 shares, a decline of 10.1% from the August 31st total of 633,900 shares. Approximately 3.1% of the shares of the company are […]